PubMed Health⌕ Search

Biomedical subjects

M C Perry

Publications and source records attributed to M C Perry.

At least 109 records · Page 6Linked to original sources
PubMed1984

Phase I clinical evaluation of cytarabine and cisplatin in patients with advanced cancer.

Studies in cell culture systems and tumor-bearing animals have demonstrated synergistic cytotoxicity of cytarabine (ara-C) and cisplatin. We have conducted a phase I trial to assess the toxic effects and tolerable doses of these drugs in patients with advanced cancer. Forty-five such patients were treated with varying dosages of ara-C infused continuously during Days 1-3 of a 28-day cycle. Cisplatin at a dose of 100 mg/m2 was administered on Day 2 of the cycle. Using this schedule, the maximally tolerated dose of ara-C in previously untreated patients was 60 mg/m2/day (180 mg/m2). Hematologic toxicity was dose-limiting with median wbc and granulocyte count nadirs of 1800 and 168/mm3, respectively. Reduction of the cisplatin dose while maintaining the ara-C dose at 60 mg/m2/day resulted in less myelosuppression, suggesting that these drugs may have synergistic effects on the bone marrow. Objective responses were seen in six of 41 evaluable patients, including five of 12 patients with non-small cell lung cancer. The severe bone marrow toxicity observed at relatively low drug doses and the 42% response rate in patients with non-small cell lung cancer suggest that the combination of ara-C and cisplatin has substantial clinical activity. Phase II trials are warranted in non-small cell lung cancer and other tumors.

Adult↗
PubMed1983

Survival, bodyweight and food consumption data obtained from life span rodent studies in isolated animal units.

A previous poster presentation proposed the use of isolated units for life span studies in rodents. This novel concept of design was considered to be the best available housing system for these studies. To further support our claim that these units provide good quality reproduceable results control data obtained from initial life span studies in the rat and mouse are reported.

Animals↗
PubMed1983

Chemoendocrine therapy vs chemotherapy alone for advanced breast cancer in postmenopausal women: preliminary report of a randomized study.

From January 1980 to August 1982 the Cancer and Leukemia Group B conducted a prospective randomized trial comparing chemoendocrine therapy with T-CAF (cyclophosphamide, adriamycin, and 5-fluorouracil plus tamoxifen) to CAF alone in postmenopausal women with advanced breast cancer. The patients were stratified by estrogen receptor (ER) status into three groups: ER-negative, ER-positive, ER-unknown. They were also stratified by dominant site of metastatic disease: visceral and other (osseous and/or soft tissue). A total of 246 eligible patients were enrolled in the study; 232 were evaluable and constitute the basis for this report. The study revealed that there was no difference in overall response frequency or response duration between T-CAF and CAF; there was no difference in response between T-CAF and CAF in ER-positive or in ER-negative patients; and there was no difference in response between T-CAF and CAF by dominant site of metastatic disease. The expected advantage of T-CAF over CAF, especially for ER-positive patients, was not observed.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1983

Hypokalemia in acute myelogenous leukemia.

Forty-two patients with acute myelogenous leukemia or one of its variants were studied at diagnosis to determine the incidence and cause(s) of hypokalemia. Forty-three percent of patients were hypokalemic, and an inappropriate renal loss of potassium was noted. This potassium wastage could not be explained by antibiotic-induced renal tubular dysfunction, lysozymuria, or alterations in renin-aldosterone secretion.

Aldosterone↗
PubMed1983

The suprahepatic gallbladder. An unusual anatomical variant.

The authors describe a case of ectopic gallbladder found lying posterior to the liver in the subdiaphragmatic space. This condition should be considered whenever the right lobe of the liver is hypoplastic and the gallbladder cannot be visualized on hepatobiliary scans or oral cholecystograms.

Gallbladder↗
PubMed1982

Addison's disease, adrenal autoantibodies and computerised adrenal tomography.

The present study describes 53 patients with Addison's disease, who attended Auckland hospitals between 1971-1980, 32 of whom presented for the first time during this period, when the mean annual incidence of Addison's disease was 4.5 cases/million population, and the respective frequency of idiopathic (auto-immune) and tuberculous aetiologies was 92 percent and 4 percent for caucasians, but 25 percent and 63 percent for Polynesians. In addition, adrenal reserve was tested by ACTH stimulation in 20 clinically non-Addisonian patients in whom circulating adrenal antibodies had been incidentally demonstrated and present for periods of up to six years, and was normal in all cases. Such antibodies therefore lack functional disease specificity. The diagnostic value of CT adrenal scanning in illustrating the contrasting appearances between tuberculous and auto-immune adrenalitis is shown in four patients.

Addison Disease↗
PubMed1982

Thyrotoxic erythrocytosis.

Erythrocytosis in a woman with hyperthyroidism prompted evaluation for other causes of an elevated hematocrit level. No underlying cause was identified, and the erythrocytosis resolved as the thyroid status returned to normal. The possibility of thyrotoxicosis should be considered in a patient with an elevated hematocrit value.

Female↗
PubMed1981

Osteogenic sarcoma following Hodgkin's disease.

The cases of two children who developed osteogenic sarcoma of the distal femur following prolonged remission of Hodgkin's disease are reported. These cases are unique in that the sarcoma developed in an area not previously irradiated. This occurrence suggests the possibility of genetic susceptibility to primary cancers in certain individuals, although prior chemotherapy may have contributed to this occurrence.

Bone Neoplasms↗
PubMed1981

Metastatic cervical adenocarcinoma from unknown primary tumor. Treatment dilemma.

Adenocarcinomas with cervical metastases as their only manifestation are infrequent. They have been grouped with metastatic squamous carcinomas of unknown primary tumor in the ear, nose, and throat literature. Most cases represent distant metastases and will have a rapid downhill course to death despite all treatment. A diligent search should be made for treatable adenocarcinomas, eg, breast, ovary, prostate, and thyroid. The primary site will be found in only a small minority of cases by any means. Radical neck dissection should not be performed when the primary tumor is not localized to the head and neck.

Adenocarcinoma↗